HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA Asks US To Lift Tariffs On Imports From China Weighing Down Supplement Firms

Executive Summary

AHPA asks USTR Katherine Tai to eliminate punitive tariffs Trump administration imposed on certain Chinese ingredients used by supplement companies. With costs up, many US supplement firms are operating on net margins of less than 10%.

You may also be interested in...



US Supplement Industry Rides Growth Amid Changes After Year Of Covid-19 Pandemic

“Many of those initial fears have abated as companies have learned more about transmission and how to protect staff,” says Tara Couch, EAS Consulting. But industry is changed and manufacturers are thinking more intently about supply chains and manufacturing processes.

UNPA On Team Awarded $300,000 US Grant For Project To Improve Natural Health Trade With China

Grant from Department of Commerce Market Development Cooperator Program funds project for four years. In addition to grant, the project partners – UNPA, National Animal Supplement Council, Eurofins Scientific testing company and China Inspections and Testing Society – get DoC assistance.

Full Plate Of Dietary Ingredients In Latest US Tariff Hikes On Chinese Imports

Consumer health industry groups plan to comment at June 17 public hearing on USTR plan for 25% tariff on imports from China not included in three earlier rounds of duties. NPA applauds USTR for allowing exclusion process for imported products valued at $200bn already hit with tariffs in 2018.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel